Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors.
L Madeline McCraryDivision of Infectious Diseases, Washington University in St Louis School of Medicine, St Louis, Missouri, USA.ORCID 0000-0002-0046-4652
Megan R CurtisDivision of Infectious Diseases, Washington University in St Louis School of Medicine, St Louis, Missouri, USA.ORCID 0000-0002-5568-3422
Jeannie C KellyDivision of Maternal-Fetal Medicine and Ultrasound, Washington University in St Louis School of Medicine, St Louis, Missouri, USA.
Jessica Elrod-GallegosDivision of Infectious Diseases, Washington University in St Louis School of Medicine, St Louis, Missouri, USA.
Patrick KojimaDivision of Infectious Diseases, Washington University in St Louis School of Medicine, St Louis, Missouri, USA.ORCID 0009-0008-4830-1482
Patricia WernerDivision of Infectious Diseases, Washington University in St Louis School of Medicine, St Louis, Missouri, USA.
Jennifer L MullersmanDivision of Infectious Diseases, Washington University in St Louis School of Medicine, St Louis, Missouri, USA.ORCID 0009-0007-2635-0657
Tracey Habrock-BachDivision of Infectious Diseases, Washington University in St Louis School of Medicine, St Louis, Missouri, USA.
Michael J DurkinDivision of Infectious Diseases, Washington University in St Louis School of Medicine, St Louis, Missouri, USA.
Laura R MarksDivision of Infectious Diseases, Washington University in St Louis School of Medicine, St Louis, Missouri, USA.
Funding
Scientific Working GroupP30AI176532 · NIAID · WASHINGTON UNIVERSITY · PI FRED M SSEWAMALA · 2024 to 2026
$5.6M
Washington University Career Development Program in Drug Abuse and AddictionK12DA041449 · NIDA · WASHINGTON UNIVERSITY · PI Laura J. Bierut, Patricia A Cavazos-Rehg · 2017 to 2026
$4.2M
The Opioid in Pregnancy: Imaging of Oxygenation, Inflammation, and Development in Brain & Placenta Project (OPIOID BPP)R01HD113199 · NICHD · WASHINGTON UNIVERSITY · PI Jeannie Chen Kelly, Yong Wang · 2023 to 2026
$3.1M
Substance Use in Pregnant People - Optimizing Retention in Treatment by Maximizing Opportunities for Management (SUPPORT-MOM)R61DA062321 · NIDA · WASHINGTON UNIVERSITY · PI BAUMANN WALKER, ANA, KELLY, JEANNIE CHEN · 2024 to 2024
$937k
Using the Transdermal Patch for Buprenorphine Induction during Pregnancy: A Pilot Randomized Controlled TrialR21DA057493 · NIDA · WASHINGTON UNIVERSITY · PI KELLY, JEANNIE CHEN · 2023 to 2024
$442k
National Institute of Allergy and Infectious Diseases 5P30AI176532National Institute of Allergy and Infectious Diseases, NIH 5P30AI176532National Institute on Drug Abuse, NIH K12 DA054999NIAID NIH HHS P30 AI176532NICHD NIH HHS R01 HD113199NIDA NIH HHS K12 DA041449NIDA NIH HHS K12 DA054999NIDA NIH HHS R21 DA057493NIDA NIH HHS R61 DA062321NIH HHS R01 HD113199NIH HHS R21 DA057493NIH HHS R61 DA062321
6 · The paper itself
Abstract
Guidelines endorse antenatal hepatitis C virus treatment following shared decision making. No clinical trial or real-world data exist for glecaprevir-pibrentasvir (GLE/PIB). We report our experience with prenatal GLE/PIB in 14 patients. Ten patients completed treatment; all achieved virologic response by or at delivery, with no maternal or neonatal safety concerns.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Real-World Experience of Hepatitis C Treatment With Glecaprevir-Pibrentasvir During Pregnancy. · full record | OpenQuestion